We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Results for
"[search-keyword]"
Sponsor content
6 result(s) found, displaying 1 to 6
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SCENESSE afamelanotide (as acetate) 16 mg implant vial.
-
Australian Public Assessment Report (AusPAR)Australian Public Assessment Report for Afamelanotide
-
Prescription medicine decision summaryTGA decision: Scenesse (afamelanotide) is approved to prevent phototoxicity in adult patients with erythropoietic protoporphyria.
-
Prescription medicine registrationActive ingredients: afamelanotide acetate.
-
Designation or determinationPriority review
-